文献速递其他结缔组织病类风湿关节炎

利妥昔单抗治疗炎症性风湿与肌肉骨骼疾病患者的COVID-19结局:队列研究

COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study.
PubMed 文献 · Lancet Rheumatol · 2021-03-25

基于法国RMD COVID-19队列1090例炎症性风湿与肌肉骨骼疾病患者,比较利妥昔单抗组(63例)与未使用组(1027例)的COVID-19严重程度。

核心结论

  • 利妥昔单抗治疗与炎症性风湿与肌肉骨骼疾病患者更严重的COVID-19结局相关。
  • 对这类患者处方利妥昔单抗需特别谨慎。

研究设计与样本

  • 法国RMD COVID-19队列研究,纳入18岁及以上炎症性风湿与肌肉骨骼疾病且高度疑似或确诊COVID-19的患者。
  • 采用逆概率治疗加权倾向评分法调整年龄、性别、高血压、糖尿病、吸烟状态、体重指数、间质性肺病、心血管疾病、癌症、糖皮质激素使用、慢性肾衰竭及基础疾病等混杂因素。

主要发现

  • 1090例患者中137例(13%)发展为严重COVID-19,89例(8%)死亡。

关键数值与推荐

  • 严重疾病定义为需入住重症监护室或导致死亡。
  • 主要终点为利妥昔单抗组与未使用组COVID-19严重程度的比较。

临床怎么用

  • 对炎症性风湿与肌肉骨骼疾病患者使用利妥昔单抗时,应评估COVID-19风险并谨慎处方。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Various observations have suggested that the course of COVID-19 might be less favourable in patients with inflammatory rheumatic and musculoskeletal diseases receiving rituximab compared with those not receiving rituximab. We aimed to investigate whether treatment with rituximab is associated with severe COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases. METHODS: In this cohort study, we analysed data from the French RMD COVID-19 cohort, which included patients aged 18 years or older with inflammatory rheumatic and musculoskeletal diseases and highly suspected or confirmed COVID-19. The primary endpoint was the severity of COVID-19 in patients treated with rituximab (rituximab group) compared with patients who did not receive rituximab (no rituximab group). Severe disease was defined as that requiring admission to an intensive care unit or leading to death. Secondary objectives were to analyse deaths and duration of hospital stay. The inverse probability of treatment weighting propensity score method was used to adjust for potential confounding factors (age, sex, arterial hypertension, diabetes, smoking status, body-mass index, interstitial lung disease, cardiovascular diseases, cancer, corticosteroid use, chronic renal failure, and the underlying disease [rheumatoid arthritis vs others]). Odds ratios and hazard ratios and their 95% CIs were calculated as effect size, by dividing the two population mean differences by their SD. This study is registered with ClinicalTrials.gov, NCT04353609. FINDINGS: Between April 15, 2020, and Nov 20, 2020, data were collected for 1090 patients (mean age 55·2 years [SD 16·4]); 734 (67%) were female and 356 (33%) were male. Of the 1090 patients, 137 (13%) developed severe COVID-19 and 89 (8%) died. After adjusting for potential confounding factors, severe disease was observed more frequently (effect size 3·26, 95% CI 1·66-6·40, p=0·0006) and the duration of hospital stay was markedly longer (0·62, 0·46-0·85, p=0·0024) in the 63 patients in the rituximab group than in the 1027 patients in the no rituximab group. 13 (21%) of 63 patients in the rituximab group died compared with 76 (7%) of 1027 patients in the no rituximab group, but the adjusted risk of death was not significantly increased in the rituximab group (effect size 1·32, 95% CI 0·55-3·19, p=0·53). INTERPRETATION: Rituximab therapy is associated with more severe COVID-19. Rituximab will have to be prescribed with particular caution in patients with inflammatory rheumatic and musculoskeletal diseases. FUNDING: None.

来源:Lancet Rheumatol,查看原文。版权归原作者所有。

引用

  1. Avouac J, Drumez E, Hachulla E, et al. COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study. Lancet Rheumatol. 2021. PMID: 33786454. doi:10.1016/S2665-9913(21)00059-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。